Skip to main navigation
Skip to search
Skip to main content
Providence Home
Search content at Providence
Home
Profiles
Research and Focus Areas
Grants and Projects
Research
Awards
Cyclooxygenase-2 inhibition in colorectal cancer: Boom or bust?
Rachel Sanborn
, Charles D. Blanke
Cancer
Oregon
Research output
:
Contribution to journal
›
Article
›
peer-review
24
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Cyclooxygenase-2 inhibition in colorectal cancer: Boom or bust?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Colorectal Carcinoma
100%
Cyclooxygenase 2
100%
Cyclooxygenase 2 Inhibitor
28%
Biological Product
14%
Programmed Cell Death
14%
Nonsteroid Antiinflammatory Agent
14%
Cancer Staging
14%
Angiogenesis
14%
Metastatic Colorectal Cancer
14%
Combination Chemotherapy
14%
Clinical Trial
14%
Colorectal Tumor
14%
Liver Metastasis
14%
Multimodality Cancer Therapy
14%
Cancer Chemotherapy
14%
Celecoxib
14%
Pharmacology, Toxicology and Pharmaceutical Science
Colorectal Carcinoma
100%
Cyclooxygenase 2
100%
COX-2 Inhibitor
28%
Clinical Trial
14%
Non-Steroidal Anti-Inflammatory Drug
14%
Celecoxib
14%
Cancer Chemotherapy
14%
Metastatic Colorectal Cancer
14%
Biological Product
14%
Chemotherapy Regimens
14%
Colorectal Tumor
14%
Liver Metastasis
14%
Cancer Staging
14%
Neuroscience
Cyclooxygenase 2
100%
Colorectal Carcinoma
100%
Chemotherapy
25%
COX-2 Inhibitor
25%
Non-Steroidal Anti-Inflammatory Drug
12%
Angiogenesis
12%
Celecoxib
12%
Programmed Cell Death
12%